# A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis

> **NCT06260709** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Novo Nordisk A/S** · enrollment: 80 (estimated)

## Conditions studied

- Transthyretin Amyloid Cardiomyopathy (ATTR CM)

## Interventions

- **DRUG:** NNC6019-0001

## Key facts

- **NCT ID:** NCT06260709
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-02-20
- **Primary completion:** 2028-02-29
- **Final completion:** 2028-08-15
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-11-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06260709

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06260709, "A Research Study to Look at Long-term Treatment With a Medicine Called NNC6019-0001 for People Who Have Heart Failure Due to Transthyretin Amyloidosis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06260709. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*